Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Susanne Buschke
O3-2-5a Phase I Trial of BI 754091, a Programmed Death Receptor 1 (PD-1) Inhibitor, in Patients With Advanced Solid Tumors
Annals of Oncology
Medicine
Oncology
Hematology
Related publications
2241. Outcomes of Program Cell Death Protein 1 (PD-1) and Programmed Death-Ligand 1(pd-L1) Inhibitor Therapy in HIV Patients With Advanced Cancer
Open Forum Infectious Diseases
Oncology
Neurology
A Phase I Study of BI 811283, an Aurora B Kinase Inhibitor, in Patients With Advanced Solid Tumors
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered With PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
Frontiers in Oncology
Cancer Research
Oncology
Phase I Study of Nivolumab, an Anti-Pd-1 Antibody, in Patients With Malignant Solid Tumors
Investigational New Drugs
Oncology
Pharmacology
Anti-Pd-1 Monoclonal Antibody MEDI0680 in a Phase I Study of Patients With Advanced Solid Malignancies
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
A Phase I Pharmacokinetic and Pharmacodynamic Study of PX-12, a Novel Inhibitor of Thioredoxin-1, in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
A Phase 1 Study of Oral Ridaforolimus in Pediatric Patients With Advanced Solid Tumors
Oncotarget
Oncology
A Phase 1 Study of Alpelisib (BYL719), an Α- Specific PI3K Inhibitor, in Japanese Patients With Advanced Solid Tumors
Cancer Science
Cancer Research
Medicine
Oncology
